About ECNP

ECNP is an independent scientific association dedicated to the science and treatment of disorders of the brain. It is the largest non-institutional supporter of applied and translational neuroscience research and education in Europe. Read more...

ECNP offers membership to established scholars in the field and all those with an active interest in applied and translational neuroscience. Corresponding membership is also open for those not resident in Europe.  To the membership pages

ECNP organises a wide range of scientific and educational activities, programmes and events across Europe, promoting the exchange of high-quality experimental and clinical research in applied and translational neuroscience and fostering young scientists and clinicians. View agenda

youth mental health

New ECNP Podcast!

In this new podcast 'Challenges in youth mental health – awareness, prevention and access to treatment', Celso Arango, Spain, and Aiste Lengvenyte, France, discuss the challenges in youth mental health including awareness, prevention and access to treatment.

Listen here

To the ECNP Podcasts series


View the programme — ECNP Workshop on Clinical Research Methods

This workshop aims at introducing early career clinicians (psychiatrists, clinical psychologists, etc) into research methodology and to promote a critical thinking approach to the scientific literature that is particularly relevant to clinical practice.

Browse here

Can we re-medicalise the psychedelic experience?

On Monday 3 April at 16.30 CEST, Guy Goodwin will talk about how the psychedelic experience emerges from brain activity. Join online for free!

More info

Clinical Outcomes in Early-Phase Clinical Trials

A new ECNP Thematic Working Group (TWG) has been established: Clinical Outcomes in Early-Phase Clinical Trials. The goal is to bring together excellent researchers and experts across disciplines from throughout Europe and beyond to increase the efficiency of early trials in the context of drug development.

Learn more

Meet stephen Brannan

New pathways for schizophrenia treatment

Stephen Brannan, USA, talked to ECNP press officer Tom Parkhill about KarXT, an oral and investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.

To the interview

364 days of full scale war in Ukraine

Watch the video with Oleg Chaban, Ukraine, Stevan Hobfoll, USA, Arieh Shalev, Israel and Robert Ursano, USA. This meeting was organised by the ECNP Traumatic Stress Network.